Exhibit 99.1

                 [LOGO] EZEM(TM)
----------------------------
Visualize a healthier world.

Company Contact:                     Investor Relations Contacts:

E-Z-EM, Inc.                         Lippert/Heilshorn & Associates, Inc.
------------                         ------------------------------------
Tom Johnson, x3317                   Kim Sutton Golodetz (kgolodetz@lhai.com)
(800) 544-4624                                            ------------------
www.ezem.com                         (212) 838-3777
------------                         Bruce Voss (bvoss@lhai.com)
                                                 --------------
                                     (310) 691-7100
                                     www.lhai.com
                                     ------------

FOR IMMEIDATE RELEASE

               E-Z-EM, INC. ANNOUNCES FINAL DISTRIBUTION RATIO FOR
                     DIVIDEND OF ANGIODYNAMICS COMMON STOCK

LAKE SUCCESS, N.Y., Oct. 4, 2004 - E-Z-EM, Inc. (Amex: EZM) today announced the
final distribution ratio for the previously announced special stock dividend of
the 9.2 million shares of common stock of its subsidiary AngioDynamics, Inc.,
(Nasdaq NM: ANGO) held by E-Z-EM. Shareowners of record at the close of business
on October 11, 2004 will receive .856377 of a share of AngioDynamics for each
outstanding share of E-Z-EM common stock held at that time. The distribution
will occur on October 30, 2004. No fractional shares will be delivered as part
of the distribution. Instead, fractional shares will be aggregated and sold on
behalf of all stockholders. The net sale proceeds will then be distributed on a
pro rata basis to the affected stockholders.

As previously announced, E-Z-EM has received a private letter ruling from the
Internal Revenue Service that the dividend will be tax-free for federal income
tax purposes to E-Z-EM and its stockholders, except for any cash received by
stockholders instead of a fractional share.

Following the record date, E-Z-EM stockholders will receive an information
statement relating to the distribution. The information statement will also be
available on E-Z-EM's website at www.ezem.com.
                                 ------------

About E-Z-EM, Inc.

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal
radiology. The Company has developed the only CT injector on the market that can
help detect contrast extravasation, the EmpowerCT(R) with patented EDA(TM)
technology; it also offers a complete product set for the virtual colonoscopy
practitioner. This product line consists of virtual colonoscopy hardware,
software, nutritional prep kits and bowel cleaners, tagging agents and a carbon
dioxide colon insufflation system.

E-Z-EM's subsidiary, AngioDynamics, manufactures a wide range of products
including angiographic, hemodialysis, PTA dilation, thrombolytic, image-guided
vascular access products and endovascular laser venous system products, as well
as drainage products. AngioDynamics' focus is on therapeutic and diagnostic
products that enable interventional physicians to treat peripheral vascular
disease and other non-coronary diseases.

                                      # # #